bluebird bio (NASDAQ:BLUE – Get Free Report) had its price target dropped by equities researchers at Robert W. Baird from $7.00 to $6.00 in a research report issued to clients and investors on Thursday, Benzinga reports. The firm presently has an “outperform” rating on the biotechnology company’s stock.
Separately, JPMorgan Chase & Co. cut bluebird bio from an “overweight” rating to a “neutral” rating in a report on Thursday. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $5.34.
Check Out Our Latest Stock Report on BLUE
bluebird bio Price Performance
Hedge Funds Weigh In On bluebird bio
Institutional investors have recently modified their holdings of the company. Allegheny Financial Group LTD acquired a new position in shares of bluebird bio during the second quarter worth approximately $25,000. Dynamic Technology Lab Private Ltd purchased a new stake in bluebird bio in the 4th quarter valued at $37,000. Sequoia Financial Advisors LLC purchased a new stake in bluebird bio in the 4th quarter valued at $37,000. Johnson Investment Counsel Inc. raised its position in bluebird bio by 111.1% in the 4th quarter. Johnson Investment Counsel Inc. now owns 27,889 shares of the biotechnology company’s stock valued at $38,000 after buying an additional 14,680 shares during the last quarter. Finally, Enterprise Bank & Trust Co purchased a new stake in bluebird bio in the 1st quarter valued at $38,000. 87.43% of the stock is owned by institutional investors and hedge funds.
bluebird bio Company Profile
bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.
Featured Articles
- Five stocks we like better than bluebird bio
- What does consumer price index measure?
- Conservative Portfolio: Strategies for Stability
- How to Calculate Return on Investment (ROI)
- Unlocking Growth: Why Arcos Dorados Belongs in Your Portfolio
- Investing in Commodities: What Are They? How to Invest in Them
- Forget Robotaxis: Electric Air Taxis are the Next Big Investment
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.